Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niven Mehra

Showing results (131-140 of 161) with videos related to

Pageof 17
Sort By:
European Urology Focus|May 5, 2020
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer RegistryJessica C L Notohardjo, Malou C P Kuppen, Hans M Westgeest, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
European Urology|June 9, 2021
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemini Sumanasuriya, George Seed, Harry Parr, et al.
British Journal of Cancer|November 1, 2025
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-studyIris S H Kloots, Peter H J Slootbeek, Sofie H Tolmeijer, et al.
Nature Communications|February 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancerMaud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyBastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO StudyChantal F Stockem, Alberto Gil-Jimenez, Hamza Ali, et al.
Clinical Genitourinary Cancer|December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Trials|November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
European Urology Oncology|July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate CancerSandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Pageof 17

Showing results (131-140 of 161) with videos related to

Sort By:
Pageof 17
European Urology Focus|May 5, 2020
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer RegistryJessica C L Notohardjo, Malou C P Kuppen, Hans M Westgeest, et al.
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
European Urology|June 9, 2021
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemini Sumanasuriya, George Seed, Harry Parr, et al.
British Journal of Cancer|November 1, 2025
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-studyIris S H Kloots, Peter H J Slootbeek, Sofie H Tolmeijer, et al.
Nature Communications|February 14, 2024
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancerMaud Rijnders, J Alberto Nakauma-González, Debbie G J Robbrecht, et al.
The Lancet. Oncology|April 2, 2026
[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyBastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO StudyChantal F Stockem, Alberto Gil-Jimenez, Hamza Ali, et al.
Clinical Genitourinary Cancer|December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Trials|November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
European Urology Oncology|July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate CancerSandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Pageof 17